Stay updated on TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.

Latest updates to the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page
- Check6 days agoChange DetectedResults and related sections have been posted (Results, Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Study Status), and the prior 'Results Submitted' entry has been removed.SummaryDifference0.6%

- Check13 days agoChange DetectedA new Revision: v3.4.2 was added to the history; notices about government funding lapse and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedThe study record history updates to show Results Submitted and Revision: v3.4.1, replacing the previous No Results Posted status; a site-wide government funding notice was also added.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now includes a Show glossary option and color-coded additions (green) and deletions (red); the revision footer updated to v3.4.0, and the No FEAR Act Data label wording was adjusted.SummaryDifference0.5%

- Check35 days agoChange DetectedAdded a new 'Study Status' entry to the version history (latest version v57 dated 2026-01-16) reflecting the current recruitment/activation status.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page history shows a new Revision: v3.3.4 replacing the previous v3.3.3, indicating a routine system update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAR-200 Combo & Cetrelimab in Bladder Cancer Clinical Trial page.